Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 48 (8), 1092-101

Additive Endocrine Therapy for Advanced Breast Cancer - Back to the Future


Additive Endocrine Therapy for Advanced Breast Cancer - Back to the Future

Per Eystein Lønning. Acta Oncol.


While novel endocrine treatment options have been implemented in the advanced - as well as adjuvant setting, recent results suggest a place for "old-fashioned" additive treatment with estrogens in advanced breast cancer. This paper reviews the biological rationale for endocrine therapy in general and additive treatment with estrogens in particular. The finding that patients becoming resistant to treatment with aromatase inhibitors may subsequently respond to estrogen therapy adds important information to our understanding of therapy resistance in general. Moreover, the return of a therapeutic option abandoned more than 20 years ago, now to be used in a different sequential setting, suggests a critical examination whether there may be other conventional treatment options still earning a place as treatment in advanced disease as well. While ablative therapies including surgical oophorectomy, hypophysectomy and adrenalectomy are not candidate treatment options due to morbidity, there are additive treatment options apart from estrogen therapy that may be considered. Androgens administered at therapeutic doses are not feasible for toxicity reasons; yet, the potential of adding androgens in small doses as adjuvant to aromatase inhibitors should be further explored. Whether patients become resistant to other treatment options may still benefit from megestrol acetate, remains to be explored.

Similar articles

  • Evolution of Endocrine Adjuvant Therapy for Early Breast Cancer
    PE Lønning. Expert Opin Investig Drugs 19 Suppl 1, S19-30. PMID 20374026. - Review
    Endocrine treatment plays a pivotal role in the adjuvant therapy of patients harbouring oestrogen and/or progesterone receptor positive breast cancer. The objective of th …
  • Aromatase Inhibitors and Breast Cancer
    WR Miller. Minerva Endocrinol 31 (1), 27-46. PMID 16498362. - Review
    Oestrogens are involved in risk to, and progression of, breast cancer. Drugs that inhibit the production of oestrogens (aromatase inhibitors, AIs), are therefore extremel …
  • Current Status of Endocrine Therapy for Advanced Breast Cancer
    KI Bland. Ann Surg Oncol 6 (8 Suppl), 4S-7S. PMID 10619452.
  • Endocrine Therapy and Other Targeted Therapies for Metastatic Breast Cancer
    SA Hussain et al. Expert Rev Anticancer Ther 4 (6), 1179-95. PMID 15606341. - Review
    The most important change in the treatment of advanced breast cancer that will emerge over the next 10 years is the shift from adjuvant tamoxifen to adjuvant aromatase in …
  • Management of Breast Cancer
    IA Cohen et al. Clin Pharm 1 (6), 515-29. PMID 6192963. - Review
    Hormonal therapy, surgical and medical ablation procedures, and the use of palliative cytotoxic and adjuvant chemotherapy in the management of breast cancer are reviewed. …
See all similar articles

Cited by 14 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources